11:09 AM EDT, 10/18/2024 (MT Newswires) -- BioNTech (BNTX) said Friday its partner OncoC4 has notified that the US Food and Drug Administration has placed their Phase 3 trial of BNT316/ONC-392 for lung cancer on a partial clinical hold.

The hold is due to varying results between squamous and non-squamous non-small cell lung cancer patients, BioNTech said in a regulatory filing.

BioNTech said the enrollment of new patients has been paused while current participants will continue receiving treatment, adding that trials for other indications will proceed without interruption.

BioNTech shares fell nearly 3% in recent trading.

Price: 111.21, Change: -3.26, Percent Change: -2.85